245 related articles for article (PubMed ID: 20824026)
1. Adjuvant Endocrine Therapy in Early Postmenopausal Breast Cancer.
Mundhenke C; Schem C; Jonat W
Breast Care (Basel); 2008; 3(5):317-324. PubMed ID: 20824026
[TBL] [Abstract][Full Text] [Related]
2. Optimizing the use of aromatase inhibitors in adjuvant therapy for postmenopausal patients with hormone-responsive early breast cancer: current and future prospects.
Jonat W; Hilpert F
J Cancer Res Clin Oncol; 2006 Jun; 132(6):343-55. PubMed ID: 16450161
[TBL] [Abstract][Full Text] [Related]
3. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
Berry J
Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
[TBL] [Abstract][Full Text] [Related]
4. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte P; Frassoldati A
Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
[TBL] [Abstract][Full Text] [Related]
6. Challenges in the endocrine management of breast cancer.
Mouridsen HT; Rose C; Brodie AH; Smith IE
Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
[TBL] [Abstract][Full Text] [Related]
7. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
Rugo HS
Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular safety profiles of aromatase inhibitors : a comparative review.
Nabholtz JM; Gligorov J
Drug Saf; 2006; 29(9):785-801. PubMed ID: 16944964
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
[TBL] [Abstract][Full Text] [Related]
10. Emerging role of aromatase inhibitors in the adjuvant setting.
Goss PE
Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
[TBL] [Abstract][Full Text] [Related]
11. Optimizing aromatase inhibitor integration into initial treatment strategies in postmenopausal women with hormone-receptor-positive early breast cancer.
Chlebowski RT
Breast Cancer Res Treat; 2008 Dec; 112 Suppl 1():25-34. PubMed ID: 19101792
[TBL] [Abstract][Full Text] [Related]
12. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
Jahanzeb M
Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
[TBL] [Abstract][Full Text] [Related]
13. Treatment strategies that effectively reduce early recurrence risk in postmenopausal women with endocrine-sensitive breast cancer: AIs upfront vs. switching.
Paepke S; Jacobs VR; Ohlinger R; Warm M; Kümmel S; Thomas A; Harbeck N; Kiechle-Bahat M
J Cancer Res Clin Oncol; 2007 Dec; 133(12):905-16. PubMed ID: 17805570
[TBL] [Abstract][Full Text] [Related]
14. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer.
Buzdar AU
Oncologist; 2003; 8(4):335-41. PubMed ID: 12897330
[TBL] [Abstract][Full Text] [Related]
15. Safety considerations of adjuvant therapy in early breast cancer in postmenopausal women.
Gradishar WJ
Oncology; 2005; 69(1):1-9. PubMed ID: 16088229
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update.
Mokbel R; Karat I; Mokbel K
Int Semin Surg Oncol; 2006 Sep; 3():31. PubMed ID: 16981992
[TBL] [Abstract][Full Text] [Related]
17. Aromatase inhibitors: a new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women.
Colozza M; Califano R; Minenza E; Dinh P; Azambuja E
Mini Rev Med Chem; 2008 Jun; 8(6):564-74. PubMed ID: 18537711
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in endocrine therapy for postmenopausal women with early breast cancer: implications for treatment and prevention.
Tobias JS
Ann Oncol; 2004 Dec; 15(12):1738-47. PubMed ID: 15550578
[TBL] [Abstract][Full Text] [Related]
19. Switching from tamoxifen to aromatase inhibitors for adjuvant endocrine therapy in postmenopausal patients with early breast cancer.
van de Velde CJ; Verma S; van Nes JG; Masterman C; Pritchard KI
Cancer Treat Rev; 2010 Feb; 36(1):54-62. PubMed ID: 19944537
[TBL] [Abstract][Full Text] [Related]
20. Sequential hormonal therapy for metastatic breast cancer after adjuvant tamoxifen or anastrozole.
Carlson RW; Henderson IC
Breast Cancer Res Treat; 2003; 80 Suppl 1():S19-26; discussion S27-8. PubMed ID: 14535531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
